Skip to main content Deutsch

Detail

Jakob Mühlbacher
Priv.-Doz. Dr. Jakob Mühlbacher, PhD

Department of General Surgery (Division of Visceral Surgery)
Position: Consultant

ORCID: 0000-0002-8592-8259
T +43 1 40400 56210
jakob.muehlbacher@meduniwien.ac.at

Further Information

Keywords

Carcinoma, Pancreatic Ductal; Complement System Proteins; Critical Illness; Intensive Care; Kidney Transplantation

Research group(s)

Grants

  • Torque Teno Virus for the prediction of humoral alloreactivity in liver transplant recipients. (2019)
    Source of Funding: Medical Scientific Fund of the Mayor of the City of Vienna, Clinical Research
    Principal Investigator

Selected publications

  1. Tomasich, E. et al. (2024) ‘Immune cell distribution and DNA methylation signatures differ between tumor and stroma enriched compartment in pancreatic ductal adenocarcinoma’, Translational Research, 271, pp. 40–51. Available at: https://doi.org/10.1016/j.trsl.2024.05.005.
  2. Mühlbacher, J. et al. (2021) ‘Anti‐interleukin‐6 antibody clazakizumab in late antibody‐mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism’, Transplant International, 34(8), pp. 1542–1552. Available at: https://doi.org/10.1111/tri.13954.
  3. Mühlbacher, J. et al. 2020. Effect of Intraoperative Goal-Directed Fluid Management on Tissue Oxygen Tension in Obese Patients: a Randomized Controlled Trial, Obesity Surgery, 31(3), pp. 1129–1138. Available at: http://dx.doi.org/10.1007/s11695-020-05106-x.
  4. Mühlbacher, J. et al., 2020. Non-invasive Chemokine Detection: Improved Prediction of Antibody-Mediated Rejection in Donor-Specific Antibody-Positive Renal Allograft Recipients. Frontiers in Medicine, 7. Available at: http://dx.doi.org/10.3389/fmed.2020.00114.
  5. Eskandary, F. et al., 2017. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial, American Journal of Transplantation, 18(4), pp. 916–926. Available at: http://dx.doi.org/10.1111/ajt.14528.